Form 4 for IDXX Idexx Laboratories
Accepted 2025-08-08 00:00:00 ET · period of report 2025-08-06 · accession 0000874716-25-000125 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-08-08 | 2025-08-06 | IDXX | Lane Michael | EVP | M - OptEx | $276.27 | +8,411 | 15.5K | +118% | +$2.32M |
| DM | 2025-08-08 | 2025-08-06 | IDXX | Lane Michael | EVP | S - Sale+OE | $627.73 | -8,411 | 9,912 | -46% | -$5.28M |
| DM | 2025-08-08 | 2025-08-06 | IDXX | Lane Michael | EVP | M - OptEx | $0.00 | -8,411 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-06 | M | A | 1,286 | $206.94 | 8,417.94 | D | — | — | (F1) Includes a total of 28.7090 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025. |
| 2 | Common | Common Stock | 2025-08-06 | M | A | 7,125 | $288.78 | 15,542.94 | D | — | — | |
| 3 | Common | Common Stock | 2025-08-06 | S | D | 300 | $628.89 | 7,131.94 | D | — | — | (F4) Represents the weighted average price of the shares sold ranging from a low of $628.82 to a high of $628.94 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 4 | Common | Common Stock | 2025-08-06 | S | D | 2,480 | $627.99 | 7,431.94 | D | — | — | (F3) Represents the weighted average price of the shares sold ranging from a low of $627.70 to a high of $628.62 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 5 | Common | Common Stock | 2025-08-06 | S | D | 5,631 | $627.56 | 9,911.94 | D | — | — | (F2) Represents the weighted average price of the shares sold ranging from a low of $626.70 to a high of $627.69 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 6 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2025-08-06 | M | D | 1,286 | $0.00 | 0 | D | $206.94 · — to 2029-02-13 | 1,286 Common Stock | (F6) Grant of option to buy 8,366 shares of Issuer common stock that became exercisable in five annual installments beginning February 14, 2020. |
| 7 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2025-08-06 | M | D | 7,125 | $0.00 | 0 | D | $288.78 · — to 2030-02-13 | 7,125 Common Stock | (F7) Grant of option to buy 7,125 shares of Issuer common stock that became exercisable in four annual installments beginning February 14, 2021. |